← 產業報告目錄

Oligonucleotide Synthesis Market by Product ((Drugs (ASO, siRNA), Synthesized Oligos (Product (Primers, Probes)), Type ((Custom, Predesigned), Reagents, Equipment), Application (Therapeutic (Rare Diseases), Research, Diagnostics) - Global Forecast to 2030

出版商 MarketsandMarkets產業別 Healthcare & Life Sciences出版日期 2025-06-05頁數 456報告編號 BT2680

授權報價

Single User Licence$4,950 USD
Multi User Licence$6,650 USD
Corporate User Licence$8,150 USD
Global User Licence$10,000 USD
洽詢購買 申請 Sample

報告摘要

The oligonucleotide synthesis market is projected to reach USD 24.7 billion by 2030 from USD 10.5 billion in 2025, at a CAGR of 18.6% during the forecast period. The growth of this market is driven by several factors, such as the increasing demand for synthesized oligonucleotides like primers & probes for several research & diagnostic applications. Rising technological advancements in oligonucleotide synthesis are also expected to contribute to market growth during the forecast period. By product, the oligonucleotide-based drugs segment accounted for the largest share of the market in 2024. By products, the market is segmented into oligonucleotide-based drugs, synthesized oligonucleotides, reagents & consumables, and equipment. In 2024, the oligonucleotide-based drugs segment accounted for the largest share of the market. The large share of this segment can be attributed to the growing acceptance of these treatments and their proven success, especially for rare & hereditary diseases. Medications such as antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) target disease-causing genes, providing precise and personalized treatments. This growing demand is fueled by advancements in RNA-targeted therapies and delivery systems, the rising prevalence of genetic diseases, and significant investments in research and development of RNA-based treatments. In 2024, by application, the therapeutic applications segment accounted for the largest share of the market. The oligonucleotide synthesis market is segmented into therapeutic applications, research applications, and diagnostic applications. In 2024, the therapeutic applications segment accounted for the largest share of the market. The growth of this market is fueled by the use of oligos such as antisense and siRNA for the treatment of neurological & rare diseases, with ongoing research aiming to expand applications into the treatment of CVD and cancer. Advancements in synthesis technology are expected to fuel the demand for efficient & cost-effective therapeutic approaches, with a comprehensive understanding of molecular disease mechanisms ensuring the discovery of innovative therapeutic targets, thereby contributing to market growth in this segment. In 2024, North America accounted for the largest share of the oligonucleotide synthesis market. In 2024, North America accounted for the largest market share, a dominance fueled by the strong presence of key industry players and a significant surge in research initiatives dedicated to advancing oligonucleotide-based therapeutics. Additionally, North America's well-established healthcare infrastructure and favorable reimbursement policies facilitate the widespread adoption of these innovative treatments, consequently driving research applications in the region. The concentration of numerous global entities also significantly contributes to this market leadership. The primary interviews conducted for this report can be categorized as follows: • By Respondent: Tier 1-25%, Tier 2-35%, and Tier 3- 40% • By Designation: C-level Executives - 30%, Directors- 45%, and Others- 25% • By Region: North America -35%, Europe - 25%, the Asia Pacific -15%, Latin America -10%, the Middle East- 10%, and Africa- 5% Danaher Corporation (US), Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Eurofins Scientific (Luxembourg), LGC Limited (UK), Agilent Technologies, Inc. (US), Kaneka Corporation (Japan), Maravai LifeSciences (US), Azenta US Inc. (US), Twist Bioscience (US), and GenScript (US) are some of the key companies profiled in the report offering products for research & diagnostic applications. Biogen (US). Alnylam Pharmaceuticals, Inc. (US), Sarepta Therapeutics, Inc. (US), AstraZeneca (UK), Astellas Pharma Inc. (Japan), Jazz Pharmaceuticals Plc (Ireland), Nippon Shinyaku, Co. Ltd. (Japan), Ionis Pharmaceuticals, Inc. (US), and Novartis AG (Switzerland) are some of the key companies profiled in the report offering products for therapeutic applications. Research Coverage: This research report categorizes oligonucleotide synthesis market by Product (Oligonucleotide-based drugs, synthesized oligonucleotide, reagents & consumables, and equipment), application (therapeutic applications, research applications, and diagnostic applications), end user (hospitals, pharmaceutical & biotechnology companies, diagnostic laboratories, CROs & CMOs, and academic & research institutes), and region (North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa). The report's scope covers detailed information regarding the primary factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the oligonucleotide synthesis market. A thorough analysis of the key industry players has been conducted to provide insights into their business overview, solutions, and services; key strategies; new product & service launches, acquisitions, and recent developments associated with the oligonucleotide synthesis market. This report covers the competitive analysis of upcoming startups in the oligonucleotide synthesis market ecosystem. Key Benefits of Buying the Report: The report will help market leaders/new entrants by providing the closest approximations of the revenue numbers for the oligonucleotide synthesis market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide information on the key market drivers, restraints, challenges, trends, and opportunities. The report provides insights on the following : • Analysis of key drivers (Increasing use of synthesized oligos in therapeutic and diagnostic applications, technological advancements in oligonucleotide synthesis, growing government investments in life science research & synthetic biology, and growing focus on personalized medicine), restraints (Complexities associated with oligonucleotide-based drugs), opportunities (Increasing pharma R&D investments in emerging economies), and challenges (Lack of standard regulations, challenges in targeted delivery of oligonucleotides) are influencing the growth of the oligonucleotide synthesis market. • Product Approvals: Detailed insights on newly approved products of the oligonucleotide synthesis market. • Market Development: Comprehensive information about lucrative markets – the report analyses the oligonucleotide synthesis market across varied regions. • Market Diversification: Exhaustive information about new products, recent developments, and investments in the oligonucleotide synthesis market. • Pipeline Analysis: Comprehensive information about products under clinical trials. • Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players, including Danaher Corporation (US), Thermo Fisher Scientific Inc. (US), and Merck KGaA (Germany), among others offering products for research & diagnostic applications. Other companies include Biogen (US), Alnylam Pharmaceuticals, Inc. (US), and Sarepta Therapeutics, Inc. (US), among others, for the therapeutic applications segment.
目錄 Table of Contents
1 INTRODUCTION 43 1.1 STUDY OBJECTIVES 43 1.2 MARKET DEFINITION 43 1.3 INCLUSIONS & EXCLUSIONS 44 1.4 MARKET SCOPE 45 1.4.1 YEARS CONSIDERED 46 1.4.2 CURRENCY CONSIDERED 46 1.5 RESEARCH LIMITATIONS 46 1.6 STAKEHOLDERS 47 1.7 SUMMARY OF CHANGES 47 2 RESEARCH METHODOLOGY 48 2.1 RESEARCH DATA 48 2.1.1 SECONDARY DATA 49 2.1.2 PRIMARY DATA 50 2.2 MARKET SIZE ESTIMATION 51 2.2.1 MARKET SIZE ASSESSMENT, SEGMENT LEVEL 55 2.3 MARKET GROWTH FORECAST 56 2.4 OLIGONUCLEOTIDE-BASED DRUGS MARKET VOLUME ESTIMATION 58 2.5 MARKET BREAKDOWN & DATA TRIANGULATION 59 2.6 STUDY ASSUMPTIONS 60 2.7 RISK ANALYSIS 60 3 EXECUTIVE SUMMARY 61 4 PREMIUM INSIGHTS 64 4.1 OLIGONUCLEOTIDE SYNTHESIS MARKET OVERVIEW 64 4.2 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION & COUNTRY (2024) 65 4.3 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2025 VS. 2030 65 4.4 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2024 66 4.5 OLIGONUCLEOTIDE SYNTHESIS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 66 5 MARKET OVERVIEW 67 5.1 INTRODUCTION 67 5.2 MARKET DYNAMICS 67 5.2.1 DRIVERS 68 5.2.1.1 Increasing use of synthesized oligos in therapeutic & diagnostic applications 68 5.2.1.2 Technological advancements 70 5.2.1.3 Growing government investments in life science research & synthetic biology 71 5.2.1.4 Growing focus on precision/personalized medicine 72 5.2.2 RESTRAINTS 72 5.2.2.1 Complexities associated with therapeutic oligonucleotides 72 5.2.3 OPPORTUNITIES 73 5.2.3.1 Increasing R&D investments by key players in emerging economies 73 5.2.4 CHALLENGES 74 5.2.4.1 Lack of standard regulations 74 5.2.4.2 Delivery of oligonucleotide drugs to specific targets 74 5.3 INDUSTRY TRENDS 74 5.3.1 GROWING FOCUS ON DEVELOPMENT OF DRUG DELIVERY TECHNOLOGIES FOR OLIGONUCLEOTIDE-BASED DRUGS 74 5.3.2 GROWING FOCUS ON TECHNOLOGY DEVELOPMENT FOR SUSTAINABLE & LARGE-SCALE SYNTHESIS OF OLIGONUCLEOTIDES 75 5.3.3 FOCUS ON ACQUISITIONS TO ENHANCE MARKET POSITION 76 5.3.4 GROWING USE OF ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS FOR TREATMENT OF NEUROLOGICAL & RARE DISEASES 77 5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 78 5.5 VALUE CHAIN ANALYSIS 79 5.6 ECOSYSTEM ANALYSIS 82 5.6.1 ROLE IN ECOSYSTEM 83 5.7 TECHNOLOGY ANALYSIS 83 5.7.1 KEY TECHNOLOGIES 84 5.7.1.1 Solid-phase synthesis 84 5.7.1.2 Liquid-phase synthesis 84 5.7.1.3 Enzymatic oligo synthesis 85 5.7.2 COMPLEMENTARY TECHNOLOGIES 85 5.7.2.1 Polymerase chain reaction (PCR) 85 5.7.2.2 Next-generation sequencing 85 5.7.2.3 Microarray analysis 86 5.7.3 ADJACENT TECHNOLOGIES 86 5.7.3.1 CRISPR 86 5.7.3.2 Lipid nanoparticles 86 5.8 PRICING ANALYSIS 87 5.8.1 AVERAGE SELLING PRICE TREND OF OLIGONUCLEOTIDE SYNTHESIS PRODUCTS, BY KEY PLAYERS, 2022−2024 87 5.8.2 AVERAGE SELLING PRICE TREND OF OLIGONUCLEOTIDE SYNTHESIS PRODUCTS, 2022−2024 89 5.8.3 AVERAGE SELLING PRICE TREND OF OLIGONUCLEOTIDE-BASED DRUGS, BY KEY PLAYERS, 2022−2024 89 5.8.4 AVERAGE SELLING PRICE OF OLIGONUCLEOTIDE SYNTHESIS PRODUCTS, BY REGION, 2024 91 5.8.5 AVERAGE PRICING TREND OF OLIGONUCLEOTIDE SYNTHESIS PRODUCTS, BY KEY PLAYERS, 2024 93 5.8.6 AVERAGE PRICING TREND OF OLIGONUCLEOTIDE-BASED DRUGS, BY REGION, 2024 94 5.9 PATENT ANALYSIS 94 5.9.1 PATENTS FILED, BY DOCUMENT TYPE, 2014–2024 94 5.10 PIPELINE ANALYSIS 97 5.11 TRADE ANALYSIS 99 5.11.1 IMPORT DATA (HS CODE 293499) 99 5.11.2 EXPORT DATA (HS CODE 293499) 101 5.12 KEY CONFERENCES & EVENTS, 2025–2026 102 5.13 TARIFF & REGULATORY LANDSCAPE 104 5.13.1 TARIFF DATA (HS CODE 2934.99, 3822.00) 104 5.13.1.1 Trade policy updates affecting oligonucleotide synthesis market, 2022−2025 104 5.13.1.2 Impact of Tariffs on pricing & supply chain 105 5.13.2 REGULATORY BODIES, GOVERNMENT AGENCIES AND OTHER ORGANIZATIONS 105 5.13.3 REGULATORY FRAMEWORK 108 5.14 PORTER’S FIVE FORCES ANALYSIS 108 5.14.1 DEGREE OF COMPETITION 109 5.14.2 BARGAINING POWER OF SUPPLIERS 109 5.14.3 BARGAINING POWER OF BUYERS 109 5.14.4 THREAT OF SUBSTITUTES 109 5.14.5 THREAT OF NEW ENTRANTS 109 5.15 KEY STAKEHOLDERS & BUYING CRITERIA 110 5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS 110 5.15.2 BUYING CRITERIA FOR END USERS 111 5.16 CASE STUDY ANALYSIS 113 5.16.1 CASE STUDY 1: THERMO FISHER SCIENTIFIC LEVERAGED ITS OLIGONUCLEOTIDE SYNTHESIS EXPERTISE TO DELIVER LARGE-SCALE DYE-LABELED OLIGONUCLEOTIDES TO ITS CLIENT 113 5.16.2 CASE STUDY 2: BAKER LAB UTILIZING TWIST BIOSCIENCES OLIGO POOLS FOR EVALUATING PROTEIN FOLDING 113 5.16.3 CASE STUDY 3: ENHANCED MOTOR FUNCTION WITH SPINRAZA TREATMENT IN ADOLESCENTS WITH LATE-ONSET SMA 114 5.17 INVESTMENT/FUNDING SCENARIO 114 5.18 IMPACT OF GENERATIVE AI ON OLIGONUCLEOTIDE SYNTHESIS MARKET 116 5.19 TRUMP TARIFF IMPACT OVERVIEW: OLIGONUCLEOTIDE SYNTHESIS MARKET 118 5.19.1 KEY TARIFF RATES 119 5.19.2 PRICE IMPACT ANALYSIS 120 5.19.3 KEY IMPACT ON VARIOUS REGIONS 121 5.19.3.1 US 121 5.19.3.2 Europe 121 5.19.3.3 APAC 122 5.19.3.4 Rest of the World 122 5.19.4 END-USE INDUSTRY IMPACT 122 5.19.4.1 Hospitals 122 5.19.4.2 Pharmaceutical & biotechnology companies 123 5.19.4.3 Diagnostic laboratories 123 5.19.4.4 CROs & CDMOs 123 5.19.4.5 Academic & research institutes 123 6 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT 124 6.1 INTRODUCTION 125 6.2 OLIGONUCLEOTIDE-BASED DRUGS 125 6.2.1 OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE 129 6.2.1.1 Antisense oligonucleotide-based drugs 130 6.2.1.1.1 Growing use of antisense oligos in oligonucleotide-based drugs to boost growth 130 6.2.1.2 siRNA oligonucleotide-based drugs 135 6.2.1.2.1 Large pipeline of products to favor market growth 135 6.2.1.3 Other oligonucleotide-based drugs 139 6.3 SYNTHESIZED OLIGONUCLEOTIDES 142 6.3.1 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT 145 6.3.1.1 Primers 145 6.3.1.1.1 Increasing applications of oligo primers in DNA sequencing and molecular diagnostics to drive growth 145 6.3.1.2 Probes 149 6.3.1.2.1 Advancements in molecular diagnostic technologies such as FISH and qPCR to support market growth 149 6.3.1.3 DNA oligonucleotides 152 6.3.1.3.1 Diverse usage of DNA oligos to support market growth 152 6.3.1.4 RNA oligonucleotides 155 6.3.1.4.1 Growing diagnostic and therapeutic applications of RNA oligos to propel growth 155 6.3.1.5 Other synthesized oligonucleotides 158 6.3.2 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE 161 6.3.2.1 Custom oligonucleotides 161 6.3.2.1.1 Increasing demand for custom oligonucleotides for therapeutic research studies to drive growth 161 6.3.2.2 Predesigned oligonucleotides 165 6.3.2.2.1 Ability of predesigned oligos to save time required in design and optimization to boost adoption 165 6.4 REAGENTS & CONSUMABLES 168 6.4.1 GROWING DEMAND FOR OLIGOS IN SEQUENCING, DRUG DESIGN, AND GENE SYNTHESIS TO DRIVE MARKET GROWTH FOR REAGENTS 168   6.5 EQUIPMENT 171 6.5.1 TECHNOLOGICAL INNOVATIONS IN OLIGONUCLEOTIDE SYNTHESIZERS TO DRIVE GROWTH IN EQUIPMENT MARKET 171 7 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION 174 7.1 INTRODUCTION 175 7.2 THERAPEUTIC APPLICATIONS 175 7.2.1 THERAPEUTIC APPLICATIONS MARKET, BY DISEASE TYPE 179 7.2.1.1 Neurological disorders 179 7.2.1.1.1 Growing research on oligonucleotide-based drugs for treatment of DMD and SMA to drive market 179 7.2.1.2 Rare diseases 183 7.2.1.2.1 High specificity & efficacy of oligo-based drugs against rare diseases to support growth 183 7.2.1.3 Other diseases 186 7.3 RESEARCH APPLICATIONS 189 7.3.1 PCR 192 7.3.1.1 Increasing use of PCR in molecular biology research to drive market 192 7.3.2 SEQUENCING 195 7.3.2.1 Advancements in sequencing technologies & low cost of DNA sequencing to boost market 195 7.3.3 OTHER RESEARCH APPLICATIONS 198 7.4 DIAGNOSTIC APPLICATIONS 201 7.4.1 INCREASING DEMAND FOR RAPID & SPECIFIC METHODS FOR DISEASE DETECTION SUPPORT MARKET GROWTH 201 8 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER 205 8.1 INTRODUCTION 206 8.2 HOSPITALS 206 8.2.1 INCREASING FDA APPROVALS FOR OLIGONUCLEOTIDE-BASED DRUGS FOR RARE DISEASES TO DRIVE MARKET 206 8.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 210 8.3.1 GROWING APPLICATIONS OF OLIGOS IN DRUG DISCOVERY & THERAPEUTICS TO PROPEL MARKET 210 8.4 DIAGNOSTIC LABORATORIES 213 8.4.1 RISING SIGNIFICANCE OF OLIGOS IN MOLECULAR DIAGNOSTICS TO FUEL MARKET 213 8.5 CONTRACT RESEARCH ORGANIZATIONS (CROS) & CONTRACT MANUFACTURING ORGANIZATIONS (CMOS) 216 8.5.1 WIDE RANGE OF CUSTOMIZED OLIGO SERVICES TO SUPPORT MARKET GROWTH 216 8.6 ACADEMIC RESEARCH INSTITUTES 220 8.6.1 GROWING USE OF OLIGOS FOR GENOMIC RESEARCH APPLICATIONS TO PROPEL MARKET 220   9 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY REGION 224 9.1 INTRODUCTION 225 9.2 NORTH AMERICA 226 9.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK 227 9.2.2 US 231 9.2.2.1 Government initiatives and strategic developments by leading players to drive market 231 9.2.3 CANADA 235 9.2.3.1 Strong research infrastructure and availability of funding to support market growth 235 9.3 EUROPE 239 9.3.1 EUROPE: MACROECONOMIC OUTLOOK 239 9.3.2 GERMANY 244 9.3.2.1 Government & private funding investments towards health research to drive market 244 9.3.3 UK 248 9.3.3.1 Strategic collaborations & partnerships between key market players to fuel market 248 9.3.4 FRANCE 251 9.3.4.1 Favorable government initiatives for genomics research to boost demand 251 9.3.5 ITALY 255 9.3.5.1 Increasing R&D expenditure for pharma & biotech companies to support market growth 255 9.3.6 SPAIN 258 9.3.6.1 Favorable funding investments for biomedical research to drive market 258 9.3.7 REST OF EUROPE 261 9.4 ASIA PACIFIC 265 9.4.1 ASIA PACIFIC: MACROECONOMIC OUTLOOK 265 9.4.2 CHINA 269 9.4.2.1 Expansion of leading pharmaceutical & biotechnology companies to drive market 269 9.4.3 JAPAN 273 9.4.3.1 Growing research initiatives & strategic developments to boost demand 273 9.4.4 INDIA 276 9.4.4.1 Development of bioclusters and improvements in healthcare infrastructure to propel market 276 9.4.5 AUSTRALIA 279 9.4.5.1 Increasing government initiatives and research funding to support market growth 279 9.4.6 SOUTH KOREA 283 9.4.6.1 Growing research activities and strategic expansions in oligonucleotide synthesis to aid market 283 9.4.7 REST OF ASIA PACIFIC 286 9.5 LATIN AMERICA 290 9.5.1 LATIN AMERICA: MACROECONOMIC OUTLOOK 290 9.5.2 BRAZIL 294 9.5.2.1 Availability of leading oligo-based therapies to support market growth 294 9.5.3 MEXICO 297 9.5.3.1 Growing adoption of NGS technology to drive market 297 9.5.4 ARGENTINA 300 9.5.4.1 Increasing research collaborations and government support to boost market 300 9.5.5 REST OF LATIN AMERICA 304 9.6 MIDDLE EAST 307 9.6.1 MIDDLE EAST: MACROECONOMIC OUTLOOK 307 9.6.2 GCC COUNTRIES 311 9.6.2.1 Saudi Arabia (KSA) 314 9.6.2.1.1 Increasing focus on research & government support to propel market 314 9.6.2.2 United Arab Emirates (UAE) 318 9.6.2.2.1 Growing focus on life sciences research to fuel market 318 9.6.2.3 Other GCC countries 321 9.6.3 REST OF MIDDLE EAST 324 9.7 AFRICA 327 9.7.1 IMPROVEMENTS IN HEALTHCARE INFRASTRUCTURE TO SUPPORT MARKET GROWTH 327 9.7.2 AFRICA: MACROECONOMIC OUTLOOK 327 10 COMPETITIVE LANDSCAPE 331 10.1 INTRODUCTION 331 10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 331 10.3 REVENUE ANALYSIS (RESEARCH & DIAGNOSTIC APPLICATIONS) 336 10.3.1 REVENUE ANALYSIS (RESEARCH & DIAGNOSTIC APPLICATIONS), 2022−2024 336 10.3.2 REVENUE ANALYSIS (THERAPEUTIC APPLICATIONS), 2022−2024 337 10.4 MARKET SHARE ANALYSIS 337 10.4.1 MARKET SHARE ANALYSIS (RESEARCH & DIAGNOSTIC APPLICATIONS), 2024 338 10.4.2 MARKET SHARE ANALYSIS (THERAPEUTIC APPLICATIONS),2024 339 10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS (RESEARCH & DIAGNOSTIC APPLICATIONS), 2024 340 10.5.1 STARS 340 10.5.2 EMERGING LEADERS 340 10.5.3 PERVASIVE PLAYERS 340 10.5.4 PARTICIPANTS 340   10.6 COMPANY EVALUATION MATRIX: KEY PLAYERS (THERAPEUTIC APPLICATIONS), 2024 341 10.6.1 STARS 342 10.6.2 EMERGING LEADERS 342 10.6.3 PERVASIVE PLAYERS 342 10.6.4 PARTICIPANTS 342 10.6.5 COMPANY FOOTPRINT: 344 10.6.5.1 Company footprint (Research & diagnostic applications) 344 10.6.5.2 Region footprint (Research & diagnostic applications) 345 10.6.5.3 Product footprint (Research & diagnostic applications) 346 10.6.5.4 Application footprint (Research & diagnostic applications) 346 10.6.5.5 Company footprint (Therapeutic applications) 347 10.6.5.6 Region footprint (Therapeutic applications) 347 10.6.5.7 Product footprint (Therapeutic applications) 348 10.6.5.8 Application footprint (Therapeutic applications) 348 10.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 349 10.7.1 PROGRESSIVE COMPANIES 349 10.7.2 RESPONSIVE COMPANIES 349 10.7.3 DYNAMIC COMPANIES 349 10.7.4 STARTING BLOCKS 349 10.7.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 351 10.7.5.1 Detailed list of key startups/SMEs 351 10.7.5.2 Competitive benchmarking of startups/SMEs 352 10.8 COMPANY VALUATION & FINANCIAL METRICS 353 10.8.1 FINANCIAL METRICS (RESEARCH & DIAGNOSTIC APPLICATIONS) 353 10.8.2 COMPANY VALUATION (RESEARCH & DIAGNOSTIC APPLICATIONS) 353 10.8.3 FINANCIAL METRICS (THERAPEUTIC APPLICATIONS) 354 10.8.4 COMPANY VALUATION (THERAPEUTIC APPLICATIONS) 354 10.9 BRAND/PRODUCT COMPARATIVE ANALYSIS 355 10.9.1 BRAND/PRODUCT COMPARATIVE ANALYSIS, BY PRODUCT (RESEARCH & DIAGNOSTIC APPLICATIONS) 355 10.9.2 BRAND/PRODUCT COMPARATIVE ANALYSIS, BY PRODUCT (THERAPEUTIC APPLICATIONS) 356 10.10 COMPETITIVE SCENARIO 357 10.10.1 PRODUCT APPROVALS 357 11 COMPANY PROFILES 360 11.1 KEY PLAYERS (RESEARCH & DIAGNOSTIC APPLICATIONS) 360 11.1.1 DANAHER CORPORATION 360 11.1.1.1 Business overview 360 11.1.1.2 Products offered 361 11.1.1.3 Recent developments 365 11.1.1.3.1 Deals 365 11.1.1.3.2 Expansions 365 11.1.1.3.3 Other developments 366 11.1.1.4 MnM view 366 11.1.1.4.1 Key strengths 366 11.1.1.4.2 Strategic choices 366 11.1.1.4.3 Weaknesses & competitive threats 366 11.1.2 THERMO FISHER SCIENTIFIC INC. 367 11.1.2.1 Business overview 367 11.1.2.2 Products offered 368 11.1.2.3 Recent developments 371 11.1.2.3.1 Deals 371 11.1.2.4 MnM view 371 11.1.2.4.1 Key strengths 371 11.1.2.4.2 Strategic choices 371 11.1.2.4.3 Weaknesses & competitive threats 371 11.1.3 MERCK KGAA 372 11.1.3.1 Business overview 372 11.1.3.2 Products offered 373 11.1.3.3 Recent developments 376 11.1.3.3.1 Deals 376 11.1.3.3.2 Expansions 376 11.1.3.4 MnM view 377 11.1.3.4.1 Key strengths 377 11.1.3.4.2 Strategic choices 377 11.1.3.4.3 Weaknesses & competitive threats 377 11.1.4 LGC LIMITED 378 11.1.4.1 Business overview 378 11.1.4.2 Products offered 379 11.1.4.3 Recent developments 381 11.1.4.3.1 Deals 381 11.1.4.3.2 Expansions 382 11.1.4.4 MnM view 382 11.1.4.4.1 Key strengths 382 11.1.4.4.2 Strategic choices 382 11.1.4.4.3 Weaknesses & competitive threats 382 11.1.5 EUROFINS SCIENTIFIC 383 11.1.5.1 Business overview 383 11.1.5.2 Products offered 384 11.1.5.3 Recent developments 385 11.1.5.3.1 Deals 385 11.1.5.3.2 Expansions 386 11.1.5.4 MnM view 386 11.1.5.4.1 Key strengths 386 11.1.5.4.2 Strategic choices 386 11.1.5.4.3 Weaknesses & competitive threats 386 11.1.6 AGILENT TECHNOLOGIES, INC. 387 11.1.6.1 Business overview 387 11.1.6.2 Products offered 388 11.1.6.3 Recent developments 389 11.1.6.3.1 Deals 389 11.1.6.3.2 Expansions 390 11.1.7 KANEKA CORPORATION 391 11.1.7.1 Business overview 391 11.1.7.2 Products offered 392 11.1.7.3 Recent developments 394 11.1.7.3.1 Expansions 394 11.1.8 MARAVAI LIFESCIENCES 395 11.1.8.1 Business overview 395 11.1.8.2 Products offered 396 11.1.8.3 Recent developments 399 11.1.8.3.1 Deals 399 11.1.8.3.2 Expansions 399 11.1.9 AZENTA US INC. 400 11.1.9.1 Business overview 400 11.1.9.2 Products offered 401 11.1.10 TWIST BIOSCIENCE 403 11.1.10.1 Business overview 403 11.1.10.2 Products offered 404 11.1.10.3 Recent developments 405 11.1.10.3.1 Deals 405 11.1.11 GENSCRIPT 406 11.1.11.1 Business overview 406 11.1.11.2 Products offered 407 11.1.11.3 Recent developments 409 11.1.11.3.1 Deals 409 11.1.11.3.2 Expansions 409 11.2 KEY PLAYERS (THERAPEUTIC APPLICATIONS) 410 11.2.1 BIOGEN 410 11.2.1.1 Business overview 410 11.2.1.2 Products offered 411 11.2.1.3 Recent developments 412 11.2.1.3.1 Product approvals 412 11.2.1.3.2 Deals 412 11.2.1.3.3 Expansions 413   11.2.1.4 MnM view 413 11.2.1.4.1 Key strengths 413 11.2.1.4.2 Strategic choices 413 11.2.1.4.3 Weaknesses & competitive threats 413 11.2.2 ALNYLAM PHARMACEUTICALS, INC. 414 11.2.2.1 Business overview 414 11.2.2.2 Products offered 415 11.2.2.3 Recent developments 416 11.2.2.3.1 Product approvals 416 11.2.2.3.2 Deals 417 11.2.2.4 MnM view 417 11.2.2.4.1 Key strengths 417 11.2.2.4.2 Strategic choices 417 11.2.2.4.3 Weaknesses & competitive threats 417 11.2.3 SAREPTA THERAPEUTICS, INC. 418 11.2.3.1 Business overview 418 11.2.3.2 Products offered 419 11.2.3.3 Recent developments 420 11.2.3.3.1 Product approvals 420 11.2.3.3.2 Expansions 420 11.2.3.4 MnM view 420 11.2.3.4.1 Key strengths 420 11.2.3.4.2 Strategic choices 420 11.2.3.4.3 Weaknesses & competitive threats 420 11.2.4 ASTRAZENECA 421 11.2.4.1 Business overview 421 11.2.4.2 Products offered 422 11.2.4.3 Recent developments 423 11.2.4.3.1 Deals 423 11.2.4.3.2 Product Approvals 423 11.2.4.4 MnM view 423 11.2.4.4.1 Key strengths 423 11.2.4.4.2 Strategic choices 423 11.2.4.4.3 Weaknesses & competitive threats 423 11.2.5 ASTELLAS PHARMA INC. 424 11.2.5.1 Business overview 424 11.2.5.2 Products offered 425 11.2.5.3 Recent developments 426 11.2.5.3.1 Deals 426 11.2.5.3.2 Product approvals 426   11.2.5.4 MnM view 426 11.2.5.4.1 Key strengths 426 11.2.5.4.2 Strategic choices 426 11.2.5.4.3 Weaknesses & competitive threats 426 11.2.6 JAZZ PHARMACEUTICALS PLC 427 11.2.6.1 Business overview 427 11.2.6.2 Products offered 428 11.2.7 NIPPON SHINYAKU, CO. LTD. 429 11.2.7.1 Business overview 429 11.2.7.2 Products offered 430 11.2.7.3 Recent developments 431 11.2.7.3.1 Deals 431 11.2.8 IONIS PHARMACEUTICALS, INC. 432 11.2.8.1 Business overview 432 11.2.8.2 Products offered 433 11.2.8.3 Recent developments 434 11.2.8.3.1 Product Approvals 434 11.2.8.3.2 Deals 434 11.2.9 NOVARTIS AG 436 11.2.9.1 Business overview 436 11.2.9.2 Products offered 437 11.2.9.3 Recent developments 438 11.2.9.3.1 Product Approvals 438 11.2.9.3.2 Deals 438 11.3 OTHER PLAYERS 439 11.3.1 OLIGOMAKER APS (PART OF TAG COPENHAGEN A/S) 439 11.3.2 BIOLEGIO B.V. 440 11.3.3 BIOLYTIC LAB PERFORMANCE, INC. 441 11.3.4 BIOCOMMA LIMITED 442 11.3.5 REVVITY (SUBSIDIARY OF HORIZON DISCOVERY LTD.) 443 11.3.6 BIO-SYNTHESIS, INC. 444 11.3.7 CREATIVE BIOGENE 445 11.3.8 REPROCELL INC. (THROUGH SUBSIDIARY BIOSERVE) 447 12 APPENDIX 448 12.1 DISCUSSION GUIDE 448 12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 452 12.3 CUSTOMIZATION OPTIONS 454 12.4 RELATED REPORTS 454 12.5 AUTHOR DETAILS 455
圖表清單 List of Tables & Figures
TABLE 1 OLIGONUCLEOTIDE SYNTHESIS MARKET: IMPACT ANALYSIS 68 TABLE 2 FDA-APPROVED OLIGONUCLEOTIDE-BASED THERAPIES (2016−2025) 69 TABLE 3 LIST OF ACQUISITIONS IN OLIGONUCLEOTIDE SYNTHESIS MARKET 76 TABLE 4 APPROVED ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS 78 TABLE 5 AVERAGE SELLING PRICE TREND OF OLIGONUCLEOTIDE SYNTHESIS PRODUCTS, BY KEY PLAYERS, 2022−2024 87 TABLE 6 AVERAGE SELLING PRICE TREND FOR OLIGONUCLEOTIDE-BASED DRUGS, BY KEY PLAYERS, 2022-2024 89 TABLE 7 AVERAGE SELLING PRICE OF OLIGONUCLEOTIDE SYNTHESIS PRODUCTS, BY REGION, 2024 91 TABLE 8 AVERAGE SELLING PRICE FOR OLIGONUCLEOTIDE-BASED DRUGS, BY REGION, 2024 94 TABLE 9 INDICATIVE LIST OF PATENTS IN OLIGONUCLEOTIDE SYNTHESIS MARKET 96 TABLE 10 IMPORT VALUE OF HS CODE 293499-COMPLIANT PRODUCTS FOR TOP 20 COUNTRIES, 2020–2024 (USD THOUSAND) 99 TABLE 11 IMPORT VOLUME FOR HS CODE 293499-COMPLIANT PRODUCTS FOR TOP 20 COUNTRIES, 2020–2024 (TONS) 100 TABLE 12 EXPORT VALUE OF HS CODE 293499-COMPLIANT PRODUCTS FOR TOP 20 COUNTRIES, 2020–2024 (USD THOUSAND) 101 TABLE 13 EXPORT VOLUME FOR HS CODE 9027-COMPLIANT PRODUCTS FOR TOP 20 COUNTRIES, 2020–2024 (TONS)S 102 TABLE 14 OLIGONUCLEOTIDE SYNTHESIS MARKET: LIST OF CONFERENCES & EVENTS 102 TABLE 15 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 105 TABLE 16 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 106 TABLE 17 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 106 TABLE 18 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 107 TABLE 19 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 107 TABLE 20 OLIGONUCLEOTIDE SYNTHESIS MARKET: PORTER’S FIVE FORCES ANALYSIS 108 TABLE 21 KEY COMPANIES IMPLEMENTING AI 117 TABLE 22 US ADJUSTED RECIPROCAL TARIFF RATES 119 TABLE 23 KEY PRODUCT-RELATED TARIFF: MISCELLANEOUS CHEMICAL PRODUCTS, PHARMACEUTICAL PRODUCTS, ORGANIC CHEMICALS. 120 TABLE 24 CRITICAL COMPONENTS EXPOSED TO TARIFF CHANGES 121 TABLE 25 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 125 TABLE 26 OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY REGION, 2023–2030 (USD MILLION) 126 TABLE 27 NORTH AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 126 TABLE 28 EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 127 TABLE 29 ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 127 TABLE 30 LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 128 TABLE 31 MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 128 TABLE 32 GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 128 TABLE 33 OLIGONUCLEOTIDE-BASED DRUGS MARKET VOLUME, BY PRODUCT, 2023–2030 (NUMBER OF VIALS) 129 TABLE 34 OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION) 130 TABLE 35 APPROVED ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS 131 TABLE 36 ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY REGION, 2023–2030 (USD MILLION) 132 TABLE 37 NORTH AMERICA: ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 132 TABLE 38 EUROPE: ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 133 TABLE 39 ASIA PACIFIC: ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 133 TABLE 40 LATIN AMERICA: ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 134 TABLE 41 MIDDLE EAST: ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 134 TABLE 42 GCC COUNTRIES: ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 134 TABLE 43 APPROVED SIRNA OLIGONUCLEOTIDE-BASED DRUGS 135 TABLE 44 SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY REGION, 2023–2030 (USD MILLION) 136 TABLE 45 NORTH AMERICA: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 136 TABLE 46 EUROPE: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 137 TABLE 47 ASIA PACIFIC: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 137 TABLE 48 LATIN AMERICA: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 138 TABLE 49 MIDDLE EAST: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 138 TABLE 50 GCC COUNTRIES: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 138 TABLE 51 APPROVED OTHER OLIGONUCLEOTIDE-BASED DRUGS 139 TABLE 52 OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY REGION, 2023–2030 (USD MILLION) 140 TABLE 53 NORTH AMERICA: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 140 TABLE 54 EUROPE: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 140 TABLE 55 ASIA PACIFIC: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 141 TABLE 56 LATIN AMERICA: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 141 TABLE 57 MIDDLE EAST: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 141 TABLE 58 GCC COUNTRIES: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 142 TABLE 59 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY REGION, 2023–2030 (USD MILLION) 143 TABLE 60 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 143 TABLE 61 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 143 TABLE 62 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 144 TABLE 63 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 144 TABLE 64 MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 144 TABLE 65 GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 145 TABLE 66 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 145 TABLE 67 OLIGONUCLEOTIDE PRIMERS MARKET, BY REGION, 2023–2030 (USD MILLION) 146 TABLE 68 NORTH AMERICA: OLIGONUCLEOTIDE PRIMERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 146 TABLE 69 EUROPE: OLIGONUCLEOTIDE PRIMERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 147 TABLE 70 ASIA PACIFIC: OLIGONUCLEOTIDE PRIMERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 147 TABLE 71 LATIN AMERICA: OLIGONUCLEOTIDE PRIMERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 148 TABLE 72 MIDDLE EAST: OLIGONUCLEOTIDE PRIMERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 148 TABLE 73 GCC COUNTRIES: OLIGONUCLEOTIDE PRIMERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 148 TABLE 74 OLIGONUCLEOTIDE PROBES MARKET, BY REGION, 2023–2030 (USD MILLION) 150 TABLE 75 NORTH AMERICA: OLIGONUCLEOTIDE PROBES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 150 TABLE 76 EUROPE: OLIGONUCLEOTIDE PROBES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 150 TABLE 77 ASIA PACIFIC: OLIGONUCLEOTIDE PROBES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 151 TABLE 78 LATIN AMERICA: OLIGONUCLEOTIDE PROBES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 151 TABLE 79 MIDDLE EAST: OLIGONUCLEOTIDE PROBES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 151 TABLE 80 GCC COUNTRIES: OLIGONUCLEOTIDE PROBES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 152 TABLE 81 DNA OLIGONUCLEOTIDES MARKET, BY REGION, 2023–2030 (USD MILLION) 153 TABLE 82 NORTH AMERICA: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 153 TABLE 83 EUROPE: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 153 TABLE 84 ASIA PACIFIC: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 154 TABLE 85 LATIN AMERICA: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 154 TABLE 86 MIDDLE EAST: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 154 TABLE 87 GCC COUNTRIES: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 155 TABLE 88 RNA OLIGONUCLEOTIDES MARKET, BY REGION, 2023–2030 (USD MILLION) 156 TABLE 89 NORTH AMERICA: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 156 TABLE 90 EUROPE: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 156 TABLE 91 ASIA PACIFIC: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 157 TABLE 92 LATIN AMERICA: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 157 TABLE 93 MIDDLE EAST: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 157 TABLE 94 GCC COUNTRIES: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 158 TABLE 95 OTHER SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY REGION, 2023–2030 (USD MILLION) 159 TABLE 96 NORTH AMERICA: OTHER SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 159 TABLE 97 EUROPE: OTHER SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 159 TABLE 98 ASIA PACIFIC: OTHER SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 160 TABLE 99 LATIN AMERICA: OTHER SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 160 TABLE 100 MIDDLE EAST: OTHER SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 160 TABLE 101 GCC COUNTRIES: OTHER SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 161 TABLE 102 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION) 161 TABLE 103 CUSTOM OLIGONUCLEOTIDES MARKET, BY REGION, 2023–2030 (USD MILLION) 162 TABLE 104 NORTH AMERICA: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 162 TABLE 105 EUROPE: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 163 TABLE 106 ASIA PACIFIC: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 163 TABLE 107 LATIN AMERICA: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 164 TABLE 108 MIDDLE EAST: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 164 TABLE 109 GCC COUNTRIES: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 164 TABLE 110 PREDESIGNED OLIGONUCLEOTIDES MARKET, BY REGION, 2023–2030 (USD MILLION) 165 TABLE 111 NORTH AMERICA: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 165 TABLE 112 EUROPE: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 166 TABLE 113 ASIA PACIFIC: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 166 TABLE 114 LATIN AMERICA: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 167 TABLE 115 MIDDLE EAST: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 167 TABLE 116 GCC COUNTRIES: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 167 TABLE 117 OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY REGION, 2023–2030 (USD MILLION) 168 TABLE 118 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 169 TABLE 119 EUROPE: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 169 TABLE 120 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 169 TABLE 121 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 170 TABLE 122 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 170 TABLE 123 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 170 TABLE 124 OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY REGION, 2023–2030 (USD MILLION) 171 TABLE 125 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 172 TABLE 126 EUROPE: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 172 TABLE 127 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 172 TABLE 128 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 173 TABLE 129 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 173 TABLE 130 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 173 TABLE 131 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 175 TABLE 132 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2023–2030 (USD MILLION) 176 TABLE 133 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 177 TABLE 134 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 177 TABLE 135 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 177 TABLE 136 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 178 TABLE 137 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2023–2030 (USD MILLION) 178 TABLE 138 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 178 TABLE 139 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION) 179 TABLE 140 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2023–2030 (USD MILLION) 180 TABLE 141 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 180 TABLE 142 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 181 TABLE 143 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 181 TABLE 144 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 182 TABLE 145 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2023–2030 (USD MILLION) 182 TABLE 146 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 182 TABLE 147 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RARE DISEASES, BY REGION, 2023–2030 (USD MILLION) 183 TABLE 148 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RARE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 184 TABLE 149 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RARE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 184 TABLE 150 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RARE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 184 TABLE 151 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RARE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 185 TABLE 152 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RARE DISEASES, BY REGION, 2023–2030 (USD MILLION) 185 TABLE 153 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RARE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 185 TABLE 154 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER DISEASES, BY REGION, 2023–2030 (USD MILLION) 186 TABLE 155 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 187 TABLE 156 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 187 TABLE 157 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 187 TABLE 158 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 188 TABLE 159 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER DISEASES, BY REGION, 2023–2030 (USD MILLION) 188 TABLE 160 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 188 TABLE 161 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 189 TABLE 162 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2023–2030 (USD MILLION) 189 TABLE 163 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 190 TABLE 164 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 190 TABLE 165 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 190 TABLE 166 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 191 TABLE 167 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2023–2030 (USD MILLION) 191 TABLE 168 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 191 TABLE 169 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PCR, BY REGION, 2023–2030 (USD MILLION) 192 TABLE 170 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PCR, BY COUNTRY, 2023–2030 (USD MILLION) 193 TABLE 171 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PCR, BY COUNTRY, 2023–2030 (USD MILLION) 193 TABLE 172 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PCR, BY COUNTRY, 2023–2030 (USD MILLION) 193 TABLE 173 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PCR, BY COUNTRY, 2023–2030 (USD MILLION) 194 TABLE 174 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PCR, BY REGION, 2023–2030 (USD MILLION) 194 TABLE 175 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PCR, BY COUNTRY, 2023–2030 (USD MILLION) 194 TABLE 176 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SEQUENCING, BY REGION, 2023–2030 (USD MILLION) 196 TABLE 177 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION) 196 TABLE 178 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION) 196 TABLE 179 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION) 197 TABLE 180 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION) 197 TABLE 181 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SEQUENCING, BY REGION, 2023–2030 (USD MILLION) 197 TABLE 182 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION) 198 TABLE 183 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER RESEARCH APPLICATIONS, BY REGION, 2023–2030 (USD MILLION) 199 TABLE 184 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 199 TABLE 185 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 199 TABLE 186 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 200 TABLE 187 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 200 TABLE 188 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER RESEARCH APPLICATIONS, BY REGION, 2023–2030 (USD MILLION) 200 TABLE 189 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 201 TABLE 190 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2023–2030 (USD MILLION) 202 TABLE 191 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 202 TABLE 192 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 202 TABLE 193 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 203 TABLE 194 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 203 TABLE 195 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2023–2030 (USD MILLION) 203 TABLE 196 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 204 TABLE 197 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION) 206 TABLE 198 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY REGION, 2023–2030 (USD MILLION) 207 TABLE 199 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION) 207 TABLE 200 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION) 208 TABLE 201 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION) 208 TABLE 202 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION) 209 TABLE 203 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY REGION, 2023–2030 (USD MILLION) 209 TABLE 204 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION) 209 TABLE 205 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION) 211 TABLE 206 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 211 TABLE 207 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 211 TABLE 208 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 212 TABLE 209 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 212 TABLE 210 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION) 212 TABLE 211 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 213 TABLE 212 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2023–2030 (USD MILLION) 214 TABLE 213 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION) 214 TABLE 214 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION) 214 TABLE 215 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION) 215 TABLE 216 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION) 215 TABLE 217 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2023–2030 (USD MILLION) 215 TABLE 218 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION) 216 TABLE 219 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY REGION, 2023–2030 (USD MILLION) 217 TABLE 220 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY COUNTRY, 2023–2030 (USD MILLION) 218 TABLE 221 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY COUNTRY, 2023–2030 (USD MILLION) 218 TABLE 222 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY COUNTRY, 2023–2030 (USD MILLION) 218 TABLE 223 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY COUNTRY, 2023–2030 (USD MILLION) 219 TABLE 224 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY REGION, 2023–2030 (USD MILLION) 219 TABLE 225 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY COUNTRY, 2023–2030 (USD MILLION) 219 TABLE 226 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION) 221 TABLE 227 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 221 TABLE 228 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 221 TABLE 229 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 222 TABLE 230 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 222 TABLE 231 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 222 TABLE 232 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 223 TABLE 233 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY REGION, 2023–2030 (USD MILLION) 225 TABLE 234 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 227 TABLE 235 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 228 TABLE 236 NORTH AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION) 228 TABLE 237 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 229 TABLE 238 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION) 229 TABLE 239 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 229 TABLE 240 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION) 230 TABLE 241 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 230 TABLE 242 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION) 231 TABLE 243 US: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 232 TABLE 244 US: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION) 233 TABLE 245 US: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 233 TABLE 246 US: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION) 233 TABLE 247 US: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 234 TABLE 248 US: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION) 234 TABLE 249 US: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 234 TABLE 250 US: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION) 235 TABLE 251 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 236 TABLE 252 CANADA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION) 236 TABLE 253 CANADA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 237 TABLE 254 CANADA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION) 237 TABLE 255 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 237 TABLE 256 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION) 238 TABLE 257 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 238 TABLE 258 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION) 238 TABLE 259 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 241 TABLE 260 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 241 TABLE 261 EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION) 242 TABLE 262 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 242 TABLE 263 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION) 242 TABLE 264 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 243 TABLE 265 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION) 243 TABLE 266 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 243 TABLE 267 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION) 244 TABLE 268 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 245 TABLE 269 GERMANY: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION) 245 TABLE 270 GERMANY: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 246 TABLE 271 GERMANY: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION) 246 TABLE 272 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 246 TABLE 273 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION) 247 TABLE 274 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 247 TABLE 275 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION) 247 TABLE 276 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 249 TABLE 277 UK: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION) 249 TABLE 278 UK: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 249 TABLE 279 UK: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION) 250 TABLE 280 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 250 TABLE 281 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION) 250 TABLE 282 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 251 TABLE 283 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION) 251 TABLE 284 FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 252 TABLE 285 FRANCE: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION) 252 TABLE 286 FRANCE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 253 TABLE 287 FRANCE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION) 253 TABLE 288 FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 253 TABLE 289 FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION) 254 TABLE 290 FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 254 TABLE 291 FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION) 254 TABLE 292 ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 255 TABLE 293 ITALY: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION) 256 TABLE 294 ITALY: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 256 TABLE 295 ITALY: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION) 256 TABLE 296 ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 257 TABLE 297 ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION) 257 TABLE 298 ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 257 TABLE 299 ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION) 258 TABLE 300 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 259 TABLE 301 SPAIN: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION) 259 TABLE 302 SPAIN: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 259 TABLE 303 SPAIN: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION) 260 TABLE 304 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 260 TABLE 305 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION) 260 TABLE 306 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 261 TABLE 307 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION) 261 TABLE 308 REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 262 TABLE 309 REST OF EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION) 262 TABLE 310 REST OF EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 263 TABLE 311 REST OF EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION) 263 TABLE 312 REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 263 TABLE 313 REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION) 264 TABLE 314 REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 264 TABLE 315 REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION) 264 TABLE 316 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 266 TABLE 317 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 266 TABLE 318 ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION) 267 TABLE 319 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 267 TABLE 320 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION) 267 TABLE 321 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 268 TABLE 322 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION) 268 TABLE 323 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 268 TABLE 324 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION) 269 TABLE 325 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 270 TABLE 326 CHINA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION) 270 TABLE 327 CHINA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 271 TABLE 328 CHINA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION) 271 TABLE 329 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 271 TABLE 330 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION) 272 TABLE 331 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 272 TABLE 332 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION) 272 TABLE 333 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 273 TABLE 334 JAPAN: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION) 274 TABLE 335 JAPAN: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 274 TABLE 336 JAPAN: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION) 274 TABLE 337 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 275 TABLE 338 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION) 275 TABLE 339 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 275 TABLE 340 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION) 276 TABLE 341 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 277 TABLE 342 INDIA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION) 277 TABLE 343 INDIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 277 TABLE 344 INDIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION) 278 TABLE 345 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 278 TABLE 346 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION) 278 TABLE 347 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 279 TABLE 348 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION) 279 TABLE 349 AUSTRALIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 280 TABLE 350 AUSTRALIA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION) 280 TABLE 351 AUSTRALIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 281 TABLE 352 AUSTRALIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION) 281 TABLE 353 AUSTRALIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 281 TABLE 354 AUSTRALIA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION) 282 TABLE 355 AUSTRALIA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 282 TABLE 356 AUSTRALIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION) 282 TABLE 357 SOUTH KOREA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 283 TABLE 358 SOUTH KOREA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION) 284 TABLE 359 SOUTH KOREA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 284 TABLE 360 SOUTH KOREA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION) 284 TABLE 361 SOUTH KOREA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 285 TABLE 362 SOUTH KOREA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION) 285 TABLE 363 SOUTH KOREA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 285 TABLE 364 SOUTH KOREA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION) 286 TABLE 365 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 287 TABLE 366 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION) 287 TABLE 367 REST OF ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 288 TABLE 368 REST OF ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION) 288 TABLE 369 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 288 TABLE 370 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION) 289 TABLE 371 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 289 TABLE 372 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION) 289 TABLE 373 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 290 TABLE 374 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 291 TABLE 375 LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION) 291 TABLE 376 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 292 TABLE 377 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION) 292 TABLE 378 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 292 TABLE 379 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION) 293 TABLE 380 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 293 TABLE 381 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION) 293 TABLE 382 BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 294 TABLE 383 BRAZIL: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION) 294 TABLE 384 BRAZIL: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 295 TABLE 385 BRAZIL: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION) 295 TABLE 386 BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 295 TABLE 387 BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION) 296 TABLE 388 BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 296 TABLE 389 BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION) 296 TABLE 390 MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 297 TABLE 391 MEXICO: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION) 298 TABLE 392 MEXICO: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 298 TABLE 393 MEXICO: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION) 298 TABLE 394 MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 299 TABLE 395 MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION) 299 TABLE 396 MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 299 TABLE 397 MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION) 300 TABLE 398 ARGENTINA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 301 TABLE 399 ARGENTINA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION) 301 TABLE 400 ARGENTINA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 302 TABLE 401 ARGENTINA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION) 302 TABLE 402 ARGENTINA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 302 TABLE 403 ARGENTINA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION) 303 TABLE 404 ARGENTINA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 303 TABLE 405 ARGENTINA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION) 303 TABLE 406 REST OF LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 304 TABLE 407 REST OF LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION) 304 TABLE 408 REST OF LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 305 TABLE 409 REST OF LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION) 305 TABLE 410 REST OF LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 305 TABLE 411 REST OF LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION) 306 TABLE 412 REST OF LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 306 TABLE 413 REST OF LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION) 306 TABLE 414 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY REGION, 2023–2030 (USD MILLION) 307 TABLE 415 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 308 TABLE 416 MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION) 308 TABLE 417 MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 309 TABLE 418 MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION) 309 TABLE 419 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 309 TABLE 420 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION) 310 TABLE 421 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 310 TABLE 422 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION) 310 TABLE 423 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 311 TABLE 424 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 311 TABLE 425 GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION) 312 TABLE 426 GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 312 TABLE 427 GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION) 312 TABLE 428 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 313 TABLE 429 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION) 313 TABLE 430 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 313 TABLE 431 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION) 314 TABLE 432 SAUDI ARABIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 315 TABLE 433 SAUDI ARABIA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION) 315 TABLE 434 SAUDI ARABIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 316 TABLE 435 SAUDI ARABIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION) 316 TABLE 436 SAUDI ARABIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 316 TABLE 437 SAUDI ARABIA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION) 317 TABLE 438 SAUDI ARABIA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 317 TABLE 439 SAUDI ARABIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION) 317 TABLE 440 UNITED ARAB EMIRATES: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 318 TABLE 441 UNITED ARAB EMIRATES: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION) 319 TABLE 442 UNITED ARAB EMIRATES: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 319 TABLE 443 UNITED ARAB EMIRATES: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION) 319 TABLE 444 UNITED ARAB EMIRATES: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 320 TABLE 445 UNITED ARAB EMIRATES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION) 320 TABLE 446 UNITED ARAB EMIRATES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 320 TABLE 447 UNITED ARAB EMIRATES: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION) 321 TABLE 448 OTHER GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 321 TABLE 449 OTHER GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION) 322 TABLE 450 OTHER GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 322 TABLE 451 OTHER GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION) 322 TABLE 452 OTHER GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 323 TABLE 453 OTHER GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION) 323 TABLE 454 OTHER GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 323 TABLE 455 OTHER GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION) 324 TABLE 456 REST OF MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 324 TABLE 457 REST OF MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION) 325 TABLE 458 REST OF MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 325 TABLE 459 REST OF MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION) 325 TABLE 460 REST OF MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 326 TABLE 461 REST OF MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION) 326 TABLE 462 REST OF MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 326 TABLE 463 REST OF MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION) 327 TABLE 464 AFRICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 328 TABLE 465 AFRICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION) 328 TABLE 466 AFRICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 329 TABLE 467 AFRICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION) 329 TABLE 468 AFRICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 329 TABLE 469 AFRICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION) 330 TABLE 470 AFRICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 330 TABLE 471 AFRICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION) 330 TABLE 472 STRATEGIES ADOPTED BY KEY PLAYERS IN OLIGONUCLEOTIDE SYNTHESIS MARKET (RESEARCH & DIAGNOSTIC APPLICATIONS), 2022–2025 332 TABLE 473 STRATEGIES ADOPTED BY KEY PLAYERS IN OLIGONUCLEOTIDE SYNTHESIS MARKET (THERAPEUTIC APPLICATIONS), 2022–2025 334 TABLE 474 OLIGONUCLEOTIDE SYNTHESIS MARKET (RESEARCH & DIAGNOSTIC APPLICATIONS): DEGREE OF COMPETITION 338 TABLE 475 OLIGONUCLEOTIDE SYNTHESIS MARKET (THERAPEUTIC APPLICATIONS): DEGREE OF COMPETITION 339 TABLE 476 OLIGONUCLEOTIDE SYNTHESIS MARKET (RESEARCH & DIAGNOSTIC APPLICATIONS): REGIONAL FOOTPRINT 345 TABLE 477 OLIGONUCLEOTIDE SYNTHESIS MARKET (RESEARCH & DIAGNOSTIC APPLICATIONS): PRODUCT FOOTPRINT 346 TABLE 478 OLIGONUCLEOTIDE SYNTHESIS MARKET (RESEARCH & DIAGNOSTIC APPLICATIONS): APPLICATION FOOTPRINT 346 TABLE 479 OLIGONUCLEOTIDE SYNTHESIS MARKET (THERAPEUTIC APPLICATIONS): REGION FOOTPRINT 347 TABLE 480 OLIGONUCLEOTIDE SYNTHESIS MARKET (THERAPEUTIC APPLICATIONS): PRODUCT FOOTPRINT 348 TABLE 481 OLIGONUCLEOTIDE SYNTHESIS MARKET (THERAPEUTIC APPLICATIONS): APPLICATION FOOTPRINT 348 TABLE 482 DETAILED LIST OF KEY STARTUPS/SMES 351 TABLE 483 COMPETITIVE BENCHMARKING OF STARTUPS/SMES 352 TABLE 484 OLIGONUCLEOTIDE SYNTHESIS MARKET: PRODUCT APPROVALS, JANUARY 2022–MAY 2025 357 TABLE 485 OLIGONUCLEOTIDE SYNTHESIS MARKET: DEALS, JANUARY 2022-MAY 2025 358 TABLE 486 OLIGONUCLEOTIDE SYNTHESIS MARKET: EXPANSIONS, JANUARY 2022-MAY 2025 359 TABLE 487 DANAHER CORPORATION: COMPANY OVERVIEW 360 TABLE 488 DANAHER CORPORATION: PRODUCTS OFFERED 361 TABLE 489 DANAHER CORPORATION: DEALS, JANUARY 2021−MAY 2025 365 TABLE 490 DANAHER CORPORATION: EXPANSIONS, JANUARY 2021−MAY 2025 365 TABLE 491 DANAHER CORPORATION: OTHER DEVELOPMENTS 366 TABLE 492 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 367 TABLE 493 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED 368 TABLE 494 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021−MAY 2025 371 TABLE 495 MERCK KGAA: COMPANY OVERVIEW 372 TABLE 496 MERCK KGAA: PRODUCTS OFFERED 373 TABLE 497 MERCK KGAA: DEALS, JANUARY 2021−MAY 2025 376 TABLE 498 MERCK KGAA: EXPANSIONS, JANUARY 2021−MAY 2025 376 TABLE 499 LGC LIMITED: COMPANY OVERVIEW 378 TABLE 500 LGC LIMITED: PRODUCTS OFFERED 379 TABLE 501 LGC LIMITED: DEALS, JANUARY 2021−MAY 2025 381 TABLE 502 LGC LIMITED: EXPANSIONS, JANUARY 2021−MAY 2025 382 TABLE 503 EUROFINS SCIENTIFIC: COMPANY OVERVIEW 383 TABLE 504 EUROFINS SCIENTIFIC: PRODUCTS OFFERED 384 TABLE 505 EUROFINS SCIENTIFIC: DEALS, JANUARY 2021−MAY 2025 385 TABLE 506 EUROFINS SCIENTIFIC: EXPANSIONS, JANUARY 2021−MAY 2025 386 TABLE 507 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW 387 TABLE 508 AGILENT TECHNOLOGIES, INC.: PRODUCTS OFFERED 388 TABLE 509 AGILENT TECHNOLOGIES, INC.: DEALS, JANUARY 2021−MAY 2025 389 TABLE 510 AGILENT TECHNOLOGIES, INC.: EXPANSIONS, JANUARY 2021−MAY 2025 390 TABLE 511 KANEKA CORPORATION: COMPANY OVERVIEW 391 TABLE 512 KANEKA CORPORATION: PRODUCTS OFFERED 392 TABLE 513 KANEKA CORPORATION: EXPANSIONS, JANUARY 2021−MAY 2025 394 TABLE 514 MARAVAI LIFESCIENCES: COMPANY OVERVIEW 395 TABLE 515 MARAVAI LIFESCIENCES: PRODUCTS OFFERED 396 TABLE 516 MARAVAI LIFESCIENCES: DEALS, JANUARY 2021−MAY 2025 399 TABLE 517 MARAVAI LIFESCIENCES: EXPANSIONS, JANUARY 2021−MAY 2025 399 TABLE 518 AZENTA US INC.: COMPANY OVERVIEW 400 TABLE 519 AZENTA US INC.: PRODUCTS OFFERED 401 TABLE 520 TWIST BIOSCIENCE: COMPANY OVERVIEW 403 TABLE 521 TWIST BIOSCIENCE: PRODUCTS OFFERED 404 TABLE 522 TWIST BIOSCIENCE: DEALS, JANUARY 2021−MAY 2025 405 TABLE 523 GENSCRIPT: COMPANY OVERVIEW 406 TABLE 524 GENSCRIPT: PRODUCTS OFFERED 407 TABLE 525 GENSCRIPT: DEALS, JANUARY 2021−MAY 2025 409 TABLE 526 GENSCRIPT: EXPANSIONS, JANUARY 2021−MAY 2025 409 TABLE 527 BIOGEN: COMPANY OVERVIEW 410 TABLE 528 BIOGEN: PRODUCTS OFFERED 411 TABLE 529 BIOGEN: PRODUCT APPROVALS, JANUARY 2021−MAY 2025 412 TABLE 530 BIOGEN: DEALS, JANUARY 2021−MAY 2025 412 TABLE 531 BIOGEN: EXPANSIONS, JANUARY 2021−MAY 2025 413 TABLE 532 ALNYLAM PHARMACEUTICALS, INC.: COMPANY OVERVIEW 414 TABLE 533 ALNYLAM PHARMACEUTICALS, INC.: PRODUCTS OFFERED 415 TABLE 534 ALNYLAM PHARMACEUTICALS INC.: PRODUCT APPROVALS, JANUARY 2021−MAY 2025 416 TABLE 535 ALNYLAM PHARMACEUTICALS INC.: DEALS, JANUARY 2021−MAY 2025 417 TABLE 536 SAREPTA THERAPEUTICS, INC.: COMPANY OVERVIEW 418 TABLE 537 SAREPTA THERAPEUTICS, INC.: PRODUCTS OFFERED 419 TABLE 538 SAREPTA THERAPEUTICS: PRODUCT APPROVALS, JANUARY 2021−MAY 2025 420 TABLE 539 SAREPTA THERAPEUTICS: EXPANSIONS, JANUARY 2021−MAY 2025 420 TABLE 540 ASTRAZENECA: COMPANY OVERVIEW 421 TABLE 541 ASTRAZENECA: PRODUCTS OFFERED 422 TABLE 542 ASTRAZENECA: DEALS, JANUARY 2021−MAY 2025 423 TABLE 543 ASTRAZENECA: PRODUCT APPROVALS, JANUARY 2021−MAY 2025 423 TABLE 544 ASTELLAS PHARMA INC.: COMPANY OVERVIEW 424 TABLE 545 ASTELLAS PHARMA INC.: PRODUCTS OFFERED 425 TABLE 546 ASTELLAS PHARMA INC.: DEALS, JANUARY 2021−MAY 2025 426 TABLE 547 ASTELLAS PHARMA INC.: PRODUCT APPROVALS, JANUARY 2021−MAY 2025 426 TABLE 548 JAZZ PHARMACEUTICALS PLC: COMPANY OVERVIEW 427 TABLE 549 JAZZ PHARMACEUTICALS PLC: PRODUCTS OFFERED 428 TABLE 550 NIPPON SHINYAKU, CO. LTD.: COMPANY OVERVIEW 429 TABLE 551 NIPPON SHINYAKU, CO. LTD.: PRODUCTS OFFERED 430 TABLE 552 NIPPON SHINYAKU, CO. LTD.: DEALS, JANUARY 2021−MAY 2025 431 TABLE 553 IONIS PHARMACEUTICALS, INC.: COMPANY OVERVIEW 432 TABLE 554 IONIS PHARMACEUTICALS, INC.: PRODUCTS OFFERED 433 TABLE 555 IONIS PHARMACEUTICALS, INC.: PRODUCT APPROVALS, JANUARY 2021−MAY 2025 434 TABLE 556 IONIS PHARMACEUTICALS, INC.: DEALS, JANUARY 2021−MAY 2025 434 TABLE 557 NOVARTIS AG: COMPANY OVERVIEW 436 TABLE 558 NOVARTIS AG: PRODUCTS OFFERED 437 TABLE 559 NOVARTIS AG: PRODUCT APPROVALS, JANUARY 2021−MAY 2025 438 TABLE 560 NOVARTIS AG: DEALS, JANUARY 2021−MAY 2025 438 TABLE 561 OLIGOMAKER APS: COMPANY OVERVIEW 439 TABLE 562 BIOLEGIO B.V.: COMPANY OVERVIEW 440 TABLE 563 BIOLYTIC LAB PERFORMANCE, INC.: COMPANY OVERVIEW 441 TABLE 564 BIOCOMMA LIMITED: COMPANY OVERVIEW 442 TABLE 565 REVVITY: COMPANY OVERVIEW 443 TABLE 566 BIO-SYNTHESIS, INC.: COMPANY OVERVIEW 444 TABLE 567 CREATIVE BIOGENE: COMPANY OVERVIEW 445 TABLE 568 REPROCELL INC.: COMPANY OVERVIEW 447 FIGURE 1 OLIGONUCLEOTIDE SYNTHESIS MARKET SEGMENTATION 45 FIGURE 2 RESEARCH DESIGN 48 FIGURE 3 BREAKDOWN OF PRIMARIES: SUPPLY- AND DEMAND-SIDE PARTICIPANTS 50 FIGURE 4 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS, 2024 51 FIGURE 5 MARKET SIZE ESTIMATION: APPROACH 1A (REVENUE SHARE ANALYSIS FOR RESEARCH & DIAGNOSTIC APPLICATIONS), 2024 52 FIGURE 6 MARKET SIZE ESTIMATION: APPROACH 1B (REVENUE SHARE ANALYSIS FOR THERAPEUTIC APPLICATIONS), 2024 52 FIGURE 7 ILLUSTRATIVE EXAMPLE OF DANAHER CORPORATION (RESEARCH & DIAGNOSTIC APPLICATIONS): REVENUE SHARE ANALYSIS, 2024 53 FIGURE 8 ILLUSTRATIVE EXAMPLE OF BIOGEN INC. (THERAPEUTIC APPLICATIONS): REVENUE SHARE ANALYSIS, 2024 53 FIGURE 9 MARKET VALIDATION FROM PRIMARY EXPERTS 55 FIGURE 10 MARKET SIZE ESTIMATION: TOP-DOWN APPROACH 55 FIGURE 11 CAGR PROJECTIONS: OLIGONUCLEOTIDE SYNTHESIS MARKET, 2025–2030 57 FIGURE 12 CAGR PROJECTIONS: OLIGONUCLEOTIDE-BASED DRUGS MARKET (THERAPEUTIC APPLICATIONS), 2025–2030 57 FIGURE 13 GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN OLIGONUCLEOTIDE SYNTHESIS MARKET 58 FIGURE 14 DATA TRIANGULATION METHODOLOGY 59 FIGURE 15 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2025 VS. 2030 (USD MILLION) 61 FIGURE 16 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION) 62 FIGURE 17 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2024−2029 (USD MILLION) 62 FIGURE 18 GEOGRAPHIC SNAPSHOT OF OLIGONUCLEOTIDE SYNTHESIS MARKET 63 FIGURE 19 RISING DEMAND FOR SYNTHESIZED OLIGOS FOR DRUG DISCOVERY & DEVELOPMENT TO DRIVE MARKET 64 FIGURE 20 THERAPEUTIC APPLICATIONS SEGMENT ACCOUNTED FOR MARKET SHARE IN US IN 2O24 65 FIGURE 21 OLIGONUCLEOTIDE-BASED DRUGS SEGMENT TO DOMINATE MARKET IN 2030 65 FIGURE 22 THERAPEUTIC APPLICATIONS SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2024 66 FIGURE 23 NORTH AMERICA TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD 66 FIGURE 24 OLIGONUCLEOTIDE SYNTHESIS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 67 FIGURE 25 REVENUE SHIFT AND NEW REVENUE POCKETS FOR OLIGONUCLEOTIDE MANUFACTURERS 78 FIGURE 26 VALUE CHAIN ANALYSIS (RESEARCH & DIAGNOSTIC APPLICATIONS)—MAXIMUM VALUE ADDED DURING MANUFACTURING PHASE 80 FIGURE 27 VALUE CHAIN ANALYSIS (THERAPEUTIC APPLICATIONS)—MAXIMUM VALUE ADDED DURING MANUFACTURING PHASE 81 FIGURE 28 ECOSYSTEM ANALYSIS OF OLIGONUCLEOTIDE SYNTHESIS MARKET 82 FIGURE 29 AVERAGE PRICING TREND OF OLIGONUCLEOTIDE SYNTHESIS PRODUCTS, 2022−2024 89 FIGURE 30 AVERAGE PRICING TREND OF OLIGONUCLEOTIDE SYNTHESIS PRODUCTS, BY KEY PLAYERS, 2024 93 FIGURE 31 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR OLIGONUCLEOTIDE SYNTHESIS PATENTS (JANUARY 2014–DECEMBER 2024) 95 FIGURE 32 OLIGONUCLEOTIDE DRUGS PIPELINE, BY DISEASE 97 FIGURE 33 OLIGONUCLEOTIDE DRUGS PIPELINE, BY PHASE 98 FIGURE 34 OLIGONUCLEOTIDE DRUGS PIPELINE, BY REGION 98 FIGURE 35 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR OLIGONUCLEOTIDE SYNTHESIS PRODUCTS: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 110 FIGURE 36 STAKEHOLDERS INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR OLIGONUCLEOTIDE SYNTHESIS PRODUCTS: HOSPITALS 110 FIGURE 37 BUYING CRITERIA OF END USERS FOR SYNTHESIZED OLIGONUCLEOTIDE PRODUCTS 111 FIGURE 38 BUYING CRITERIA OF HOSPITALS FOR SYNTHESIZED OLIGONUCLEOTIDE PRODUCTS 112 FIGURE 39 NIH FUNDING FOR OLIGONUCLEOTIDE SYNTHESIS PROJECTS, 2014–2024 115 FIGURE 40 AI USE CASES 117 FIGURE 41 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET SNAPSHOT 226 FIGURE 42 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET SNAPSHOT 240 FIGURE 43 OLIGONUCLEOTIDE SYNTHESIS MARKET: REVENUE ANALYSIS (RESEARCH & DIAGNOSTIC APPLICATIONS), 2022–2024 336 FIGURE 44 OLIGONUCLEOTIDE SYNTHESIS MARKET: REVENUE ANALYSIS (THERAPEUTIC APPLICATIONS), 2022–2024 337 FIGURE 45 OLIGONUCLEOTIDE SYNTHESIS MARKET SHARE ANALYSIS (RESEARCH & DIAGNOSTIC APPLICATIONS), BY KEY PLAYER, 2024 338 FIGURE 46 MARKET SHARE ANALYSIS (THERAPEUTIC APPLICATIONS), BY KEY PLAYER, 2024 339 FIGURE 47 OLIGONUCLEOTIDE SYNTHESIS MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS (RESEARCH & DIAGNOSTIC APPLICATIONS), 2024 341 FIGURE 48 OLIGONUCLEOTIDE SYNTHESIS MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS (THERAPEUTIC APPLICATIONS), 2024 343 FIGURE 49 OLIGONUCLEOTIDE SYNTHESIS MARKET (RESEARCH & DIAGNOSTIC APPLICATIONS): COMPANY FOOTPRINT 344 FIGURE 50 OLIGONUCLEOTIDE SYNTHESIS MARKET (THERAPEUTIC APPLICATIONS): COMPANY FOOTPRINT 347 FIGURE 51 OLIGONUCLEOTIDE SYNTHESIS MARKET: COMPANY EVALUATION MATRIX FOR STARTUPS/SMES, 2024 350 FIGURE 52 EV/EBITDA OF KEY VENDORS (RESEARCH & DIAGNOSTIC APPLICATIONS) 353 FIGURE 53 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS (RESEARCH & DIAGNOSTIC APPLICATIONS) 353 FIGURE 54 EV/EBITDA OF KEY VENDORS (THERAPEUTIC APPLICATIONS) 354 FIGURE 55 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS (THERAPEUTIC APPLICATIONS) 354 FIGURE 56 BRAND/PRODUCT COMPARATIVE ANALYSIS, BY PRODUCT (RESEARCH & DIAGNOSTIC APPLICATIONS) 355 FIGURE 57 BRAND/PRODUCT COMPARATIVE ANALYSIS, BY PRODUCT (THERAPEUTIC APPLICATIONS) 356 FIGURE 58 DANAHER CORPORATION: COMPANY SNAPSHOT (2024) 361 FIGURE 59 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2024) 368 FIGURE 60 MERCK KGAA: COMPANY SNAPSHOT (2024) 373 FIGURE 61 LGC LIMITED: COMPANY SNAPSHOT (2024) 379 FIGURE 62 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2024) 384 FIGURE 63 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2024) 388 FIGURE 64 KANEKA CORPORATION: COMPANY SNAPSHOT (2024) 392 FIGURE 65 MARAVAI LIFESCIENCES: COMPANY SNAPSHOT (2024) 396 FIGURE 66 AZENTA US INC.: COMPANY SNAPSHOT (2024) 401 FIGURE 67 TWIST BIOSCIENCE: COMPANY SNAPSHOT (2024) 404 FIGURE 68 GENSCRIPT: COMPANY SNAPSHOT (2024) 407 FIGURE 69 BIOGEN: COMPANY SNAPSHOT (2024) 411 FIGURE 70 ALNYLAM PHARMACEUTICALS, INC.: COMPANY SNAPSHOT (2024) 415 FIGURE 71 SAREPTA THERAPEUTICS: COMPANY SNAPSHOT (2024) 419 FIGURE 72 ASTRAZENECA: COMPANY SNAPSHOT (2024) 422 FIGURE 73 ASTELLAS PHARMA INC.: COMPANY SNAPSHOT (2024) 425 FIGURE 74 JAZZ PHARMACEUTICALS PLC: COMPANY SNAPSHOT (2024) 428 FIGURE 75 NIPPON SHINYAKU, CO. LTD.: COMPANY SNAPSHOT (2024) 430 FIGURE 76 IONIS PHARMACEUTICALS, INC.: COMPANY SNAPSHOT (2024) 432 FIGURE 77 NOVARTIS AG: COMPANY SNAPSHOT (2024) 437

同分類最新報告（醫療與生命科學）

查看醫療與生命科學全部報告 →

量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們